PediatricMercy Children's Hospital is a regional resource for advanced pediatric care. We offer a centralized location for advanced pediatric research, care and education, anchored in a major network of children’s specialists.

Financial AssistanceMercy recognizes the difficulty unexpected medical problems can cause to your finances. We are here to help so that patients can obtain medical benefits from federal, state and hospital programs.

Pay Your BillOur online Patient e-Billing has been developed to help you manage your busy schedule. Paying your bills online is quick and easy. Pay now.

Detailed Description:The ION™ stent is the third-generation Boston Scientific (BSC) paclitaxel-eluting coronary stent. It is designed for improved performance specific to deliverability and radio-opacity while maintaining a similar drug release profile of the TAXUS Express and TAXUS Liberté stents. Following PMA approval from the FDA for the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System the ION US Post-Approval study will compile real-world clinical outcomes data for the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System in routine clinical practice. Post-approval studies of drug-eluting stents (DES) provide an opportunity to observe and assess patient outcomes and technology performance in a real-world setting.

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

CriteriaInclusion Criteria:Consecutive subjects receiving one or more ION(TM)Coronary StentsExclusion Criteria:Subjects not clinically indicated to receive an ION (TM)Coronary Stent